XY028-140 is a selective CDK4/CDK6 degrader. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity in cancer cells[1].
A375 melanoma and T47D breast cancer cells are treated with 0.3 or 1 µμ XY028-140 for 24 hours. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity[1]. T47D breast cancer cells are treated with 0.03, 0.1, 0.3, 1, or 3 µμ XY028-140 for 11 days. XY028-140 inhibits cancer cell proliferation in breast cancer cells[1].
[1]. Jian Jin, et al. Compositions and methods for treating cdk4/6-mediated cancer. WO2018106870A1.